Omeros (NASDAQ:OMER) Shares Up 10.3% – Should You Buy?

Omeros Co. (NASDAQ:OMER)’s share price shot up 10.3% on Friday . The stock traded as high as $10.92 and last traded at $10.85. Approximately 474,122 shares changed hands during mid-day trading, a decline of 11% from the average daily volume of 533,973 shares. The stock had previously closed at $9.84.

Analysts Set New Price Targets

A number of equities analysts have issued reports on OMER shares. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. D. Boral Capital began coverage on shares of Omeros in a report on Monday, December 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Finally, Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Trading Up 11.0 %

The company has a market cap of $632.81 million, a PE ratio of -4.73 and a beta of 1.97. The business has a fifty day simple moving average of $8.18 and a two-hundred day simple moving average of $5.57.

Institutional Trading of Omeros

Several large investors have recently bought and sold shares of OMER. Barclays PLC lifted its stake in Omeros by 121.3% in the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 51,873 shares in the last quarter. Geode Capital Management LLC lifted its position in Omeros by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock worth $5,318,000 after buying an additional 6,839 shares in the last quarter. MML Investors Services LLC boosted its stake in Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 3,000 shares during the last quarter. Jane Street Group LLC grew its holdings in Omeros by 15.9% in the 3rd quarter. Jane Street Group LLC now owns 58,277 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 8,010 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Omeros in the 3rd quarter worth $305,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.